Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Goldfinch Bio to Present at the 38th Annual J.P. Morgan Healthcare Conference


Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present at the 38th Annual J.P. Morgan Healthcare Conference. During the presentation, Dr. Johnson will provide a review of 2019 accomplishments and introduce the Company's 2020 strategic outlook. The presentation will take place on Tuesday, January 14, 2020 at 12:00 p.m. PT at the Westin St. Francis in San Francisco.

About Goldfinch Bio

Goldfinch Bio, Inc. is a clinical stage biotechnology company that leverages a genomics-based, precision medicine approach to discovering and developing kidney disease treatments. Its Kidney Genome AtlasTM is a proprietary biology platform that drives candidate discovery, patient selection and biomarker development. The Company's lead candidate, GFB-887, is a transient receptor potential canonical 5 (TRPC5) ion channel inhibitor being evaluated in a Phase 1 clinical trial for the treatment of kidney diseases. Goldfinch Bio is also developing GFB-024, a peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody, for the treatment of rare and metabolic kidney diseases and expects to submit an IND in the second half of 2020. Goldfinch Bio, headquartered in Cambridge, Massachusetts, was launched in 2016 by Third Rock Ventures and has an established strategic collaboration with Gilead Sciences, Inc. For more information about Goldfinch Bio, visit www.goldfinchbio.com.


These press releases may also interest you

at 10:00
Iris Wellness Group Launches Outpatient Drug and Alcohol Detox Program in Chattanooga, TN
Iris Wellness Group has introduced an Outpatient Drug and Alcohol Detox Program in Chattanooga, TN, offering personalized care for individuals grappling with addiction. Launched on April 15th, 2024, this unique detox program allows patients to...

at 10:00
CREO's Mike Townley Receives Triangle Business Journal's 2024 Life Sciences Award
CREO Inc., the preferred consultancy to the world's most promising companies that seek to improve human health, today announced that Mike Townley, President and Co-Founder, has been honored with...

at 10:00
PatientRightsAdvocate.org files Amicus Brief in U.S. Department of Labor Case Against Blue Cross and Blue Shield of Minnesota
PatientRightsAdvocate.org filed an amicus brief in the case of Secretary Julie A. Su, Acting Secretary of Labor v. Blue Cross and Blue Shield (BCBS) of Minnesota, arguing that their motion to dismiss the case should be denied on the basis that BCBS...

at 09:38
Nonprofits from Inception Fertility and Caden Lane Team Up to Expand Financial Accessibility to Fertility Care
The Wyatt Foundation and The Conceive Fertility Foundation announce today a joint partnership that will award $15,000 grants to five individuals/couples who need in vitro fertility (IVF) to build their families. Launching during National Infertility...

at 09:38
Commons Clinic Invests $9.75M in Advanced Spine Surgery Center; Launches Next-Gen Ambulatory Surgical Platform "Theater"
New platform and surgery center investment adds advanced facility capabilities to specialty care network, strengthening in-person treatment and attracting leading orthopedic surgeons and physiciansWith Theater launch, value-based MSK care visionary...

at 09:34
Bulletin from annual general meeting in Medicover AB (publ)
The below resolutions were passed at Medicover's annual general meeting (the "AGM") held today on 26 April 2024. Election of the board of directors and auditor The AGM resolved, in accordance with the proposal from the nomination committee, that the...

More news about Health...


News published on and distributed by: